Company profile

Cellphire Therapeutics, Inc.

cellphire.comHeadquarters: United States
Product Vendor
Cellphire Therapeutics, Inc. logo

Primary focus

Developing next-generation platelet-derived therapeutics to address critical bleeding issues in trauma, surgery, and critical care settings.

Why it’s included

The company develops and manufactures freeze-dried platelet-derived hemostatic products such as Thrombosomes and CLPH-211, explicitly designed for hemorrhagic shock and critical bleeding with extended shelf life and rapid reconstitution, directly matching the topic's requirements.

Relevant capabilities

  • Lyophilization of platelets to produce a long‑shelf‑life hemostatic
  • Cryopreservation of platelets using DMSO for extended frozen storage
  • Apheresis platelet pooling and donor processing (leukoreduction, irradiation)
  • cGMP / cleanroom manufacturing for cellular biologics (ISO 7 suites)
  • Analytical testing and lot release (sterility, endotoxin, potency, identity)
Commercial sectorShelf-Stable and Extended-Storage Blood Components
Technology classesCryopreserved platelets (DMSO, -80°C), Platelet-derived hemostatic particles, Freeze-dried platelets (trehalose-based), Pathogen reduction for blood components, Blood bags and storage containers

Relevant commercial products

  • Lyophilized platelet‑derived hemostatic (freeze‑dried activated platelets)
  • DMSO‑stabilized cryopreserved platelet suspension (frozen activated platelets)

Relevant patents

4 families, 5 publications
  • Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use US-8486617-B2
  • Platelet derivative compositions, and methods of making and using such compositions US-12702682-B2
  • Methods using freeze-dried platelet derivative compositions for restoring hemostasis in a subject US-12295972-B2
  • Freeze-dried platelets, method of making and method of use as a diagnostic agent US-8097403-B2

← Back to what’s inside this report